This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.
-
Working with individual set: BLCA-TP
-
Number of patients in set: 395
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:BLCA-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 53
-
Mutations seen in COSMIC: 749
-
Significantly mutated genes in COSMIC territory: 24
-
Significantly mutated genesets: 23
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 395 MAFs of type "Broad"
-
Total number of mutations in input MAFs: 138385
-
After removing 10 mutations outside chr1-24: 138375
-
After removing 2579 blacklisted mutations: 135796
-
After removing 3961 noncoding mutations: 131835
-
After collapsing adjacent/redundant mutations: 126949
-
Number of mutations before filtering: 126949
-
After removing 6587 mutations outside gene set: 120362
-
After removing 199 mutations outside category set: 120163
-
After removing 4 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 113373
Table 1. Get Full Table Table representing breakdown of mutations by type.
| type | count |
|---|---|
| Frame_Shift_Del | 1521 |
| Frame_Shift_Ins | 584 |
| In_Frame_Del | 405 |
| In_Frame_Ins | 56 |
| Missense_Mutation | 76694 |
| Nonsense_Mutation | 7163 |
| Nonstop_Mutation | 177 |
| Silent | 30062 |
| Splice_Site | 3044 |
| Translation_Start_Site | 457 |
| Total | 120163 |
Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.
| category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
|---|---|---|---|---|---|---|
| Tp*C->(T/G) | 45397 | 1516381424 | 3e-05 | 30 | 3.8 | 3 |
| Tp*C->A | 4263 | 1516381424 | 2.8e-06 | 2.8 | 0.36 | 4 |
| (A/C/G)p*C->mut | 18068 | 4291475797 | 4.2e-06 | 4.2 | 0.53 | 3.2 |
| A->mut | 9404 | 5611559704 | 1.7e-06 | 1.7 | 0.21 | 3.9 |
| indel+null | 12776 | 11419416925 | 1.1e-06 | 1.1 | 0.14 | NaN |
| double_null | 190 | 11419416925 | 1.7e-08 | 0.017 | 0.0021 | NaN |
| Total | 90098 | 11419416925 | 7.9e-06 | 7.9 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom). If the figure is unpopulated, then full coverage is assumed (e.g. MutSig CV doesn't use WIGs and assumes full coverage).
Figure 1.
Figure 2. Patients counts and rates file used to generate this plot: BLCA-TP.patients.counts_and_rates.txt
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Figure 3. Get High-res Image SNV Mutation rate lego plot for entire set. Each bin is normalized by base coverage for that bin. Colors represent the six SNV types on the upper right. The three-base context for each mutation is labeled in the 4x4 legend on the lower right. The fractional breakdown of SNV counts is shown in the pie chart on the upper left. If this figure is blank, not enough information was provided in the MAF to generate it.
Figure 4. Get High-res Image SNV Mutation rate lego plots for 4 slices of mutation allele fraction (0<=AF<0.1, 0.1<=AF<0.25, 0.25<=AF<0.5, & 0.5<=AF) . The color code and three-base context legends are the same as the previous figure. If this figure is blank, not enough information was provided in the MAF to generate it.
Figure 5. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: Tp*C->(T/G)
-
n2 = number of nonsilent mutations of type: Tp*C->A
-
n3 = number of nonsilent mutations of type: (A/C/G)p*C->mut
-
n4 = number of nonsilent mutations of type: A->mut
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 53. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).
| rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TP53 | tumor protein p53 | 474723 | 226 | 196 | 118 | 7 | 59 | 3 | 79 | 16 | 67 | 2 | 1.2e-15 | <1.00e-15 | <3.61e-12 |
| 2 | KDM6A | lysine (K)-specific demethylase 6A | 1477683 | 107 | 103 | 91 | 6 | 9 | 2 | 5 | 6 | 79 | 6 | 0.016 | <1.00e-15 | <3.61e-12 |
| 3 | RB1 | retinoblastoma 1 (including osteosarcoma) | 1017077 | 73 | 70 | 66 | 1 | 4 | 1 | 0 | 3 | 59 | 6 | 0.00025 | <1.00e-15 | <3.61e-12 |
| 4 | ERCC2 | excision repair cross-complementing rodent repair deficiency, complementation group 2 (xeroderma pigmentosum D) | 842148 | 39 | 38 | 23 | 3 | 15 | 1 | 6 | 17 | 0 | 0 | 0.0028 | <1.00e-15 | <3.61e-12 |
| 5 | CDKN2A | cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | 290850 | 30 | 26 | 22 | 0 | 8 | 3 | 6 | 0 | 13 | 0 | 0.0022 | <1.00e-15 | <3.61e-12 |
| 6 | TBC1D12 | TBC1 domain family, member 12 | 558145 | 50 | 49 | 4 | 1 | 48 | 0 | 1 | 0 | 1 | 0 | 0.0004 | 1.89e-15 | 4.77e-12 |
| 7 | ELF3 | E74-like factor 3 (ets domain transcription factor, epithelial-specific ) | 441519 | 58 | 46 | 48 | 0 | 22 | 2 | 7 | 4 | 21 | 2 | 1e-05 | 1.89e-15 | 4.77e-12 |
| 8 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 1292933 | 94 | 86 | 35 | 4 | 71 | 3 | 5 | 14 | 1 | 0 | 0.000043 | 2.11e-15 | 4.77e-12 |
| 9 | CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 191623 | 38 | 35 | 30 | 1 | 6 | 0 | 2 | 0 | 25 | 5 | 0.11 | 3.66e-15 | 6.82e-12 |
| 10 | STAG2 | stromal antigen 2 | 1518100 | 60 | 56 | 53 | 8 | 11 | 1 | 2 | 3 | 42 | 1 | 0.56 | 3.77e-15 | 6.82e-12 |
| 11 | ARID1A | AT rich interactive domain 1A (SWI-like) | 2294479 | 121 | 97 | 107 | 8 | 28 | 4 | 6 | 3 | 76 | 4 | 0.00038 | 6.11e-15 | 1.00e-11 |
| 12 | ZFP36L1 | zinc finger protein 36, C3H type-like 1 | 400644 | 33 | 29 | 32 | 2 | 7 | 0 | 5 | 1 | 16 | 4 | 0.068 | 6.77e-15 | 1.02e-11 |
| 13 | FGFR3 | fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) | 720414 | 64 | 56 | 18 | 6 | 35 | 1 | 13 | 12 | 3 | 0 | 0.00025 | 8.10e-15 | 1.13e-11 |
| 14 | RHOB | ras homolog gene family, member B | 234807 | 30 | 26 | 18 | 0 | 15 | 2 | 11 | 2 | 0 | 0 | 0.000024 | 9.44e-15 | 1.22e-11 |
| 15 | RHOA | ras homolog gene family, member A | 236210 | 19 | 18 | 15 | 1 | 11 | 2 | 4 | 2 | 0 | 0 | 0.017 | 3.67e-14 | 4.43e-11 |
| 16 | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 249368 | 21 | 17 | 13 | 1 | 2 | 0 | 12 | 1 | 6 | 0 | 0.0076 | 1.67e-13 | 1.89e-10 |
| 17 | NFE2L2 | nuclear factor (erythroid-derived 2)-like 2 | 704785 | 25 | 24 | 16 | 0 | 14 | 1 | 5 | 4 | 1 | 0 | 0.01 | 6.55e-12 | 6.97e-09 |
| 18 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 271766 | 14 | 14 | 6 | 0 | 1 | 1 | 11 | 1 | 0 | 0 | 0.097 | 1.47e-10 | 1.48e-07 |
| 19 | KLF5 | Kruppel-like factor 5 (intestinal) | 444131 | 24 | 23 | 21 | 3 | 9 | 4 | 3 | 1 | 7 | 0 | 0.28 | 1.87e-10 | 1.78e-07 |
| 20 | EP300 | E1A binding protein p300 | 2895237 | 77 | 61 | 73 | 7 | 25 | 4 | 8 | 11 | 28 | 1 | 0.01 | 5.23e-10 | 4.73e-07 |
| 21 | HIST1H3B | histone cluster 1, H3b | 163925 | 12 | 12 | 9 | 1 | 10 | 2 | 0 | 0 | 0 | 0 | 0.054 | 2.31e-08 | 1.91e-05 |
| 22 | C3orf70 | chromosome 3 open reading frame 70 | 289078 | 17 | 17 | 10 | 0 | 12 | 0 | 2 | 1 | 2 | 0 | 0.023 | 2.33e-08 | 1.91e-05 |
| 23 | FBXW7 | F-box and WD repeat domain containing 7 | 976750 | 38 | 32 | 28 | 4 | 12 | 0 | 12 | 1 | 13 | 0 | 0.096 | 1.12e-07 | 8.78e-05 |
| 24 | PSIP1 | PC4 and SFRS1 interacting protein 1 | 657713 | 21 | 20 | 20 | 1 | 7 | 0 | 1 | 0 | 13 | 0 | 0.18 | 2.59e-07 | 0.000195 |
| 25 | FOXQ1 | forkhead box Q1 | 140689 | 14 | 14 | 9 | 5 | 4 | 1 | 1 | 0 | 8 | 0 | 0.67 | 3.23e-07 | 0.000234 |
| 26 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 406737 | 14 | 14 | 13 | 0 | 6 | 1 | 3 | 1 | 3 | 0 | 0.043 | 9.08e-07 | 0.000631 |
| 27 | TSC1 | tuberous sclerosis 1 | 1404707 | 34 | 33 | 30 | 4 | 4 | 0 | 5 | 1 | 24 | 0 | 0.15 | 1.06e-06 | 0.000707 |
| 28 | CFHR4 | complement factor H-related 4 | 400705 | 14 | 13 | 14 | 1 | 7 | 0 | 1 | 4 | 2 | 0 | 0.27 | 1.78e-06 | 0.00115 |
| 29 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 470985 | 16 | 14 | 15 | 0 | 6 | 0 | 0 | 2 | 8 | 0 | 0.087 | 3.41e-06 | 0.00213 |
| 30 | METTL3 | methyltransferase like 3 | 700013 | 22 | 18 | 20 | 1 | 11 | 1 | 4 | 3 | 3 | 0 | 0.021 | 8.54e-06 | 0.00515 |
| 31 | ZNF511 | zinc finger protein 511 | 239152 | 10 | 10 | 10 | 1 | 4 | 0 | 5 | 0 | 1 | 0 | 0.22 | 1.33e-05 | 0.00756 |
| 32 | FOXA1 | forkhead box A1 | 405482 | 14 | 14 | 13 | 2 | 3 | 1 | 1 | 0 | 9 | 0 | 0.7 | 1.34e-05 | 0.00756 |
| 33 | DIAPH2 | diaphanous homolog 2 (Drosophila) | 1162282 | 22 | 21 | 19 | 1 | 10 | 1 | 3 | 5 | 2 | 1 | 0.058 | 1.56e-05 | 0.00857 |
| 34 | ZFP36L2 | zinc finger protein 36, C3H type-like 2 | 281523 | 20 | 17 | 15 | 4 | 9 | 1 | 2 | 2 | 5 | 1 | 0.38 | 2.46e-05 | 0.0131 |
| 35 | BTG2 | BTG family, member 2 | 137927 | 8 | 8 | 8 | 1 | 3 | 0 | 4 | 0 | 1 | 0 | 0.2 | 2.63e-05 | 0.0136 |
Figure S1. This figure depicts the distribution of mutations and mutation types across the TP53 significant gene.
Figure S2. This figure depicts the distribution of mutations and mutation types across the KDM6A significant gene.
Figure S3. This figure depicts the distribution of mutations and mutation types across the RB1 significant gene.
Figure S4. This figure depicts the distribution of mutations and mutation types across the ERCC2 significant gene.
Figure S5. This figure depicts the distribution of mutations and mutation types across the CDKN2A significant gene.
Figure S6. This figure depicts the distribution of mutations and mutation types across the TBC1D12 significant gene.
Figure S7. This figure depicts the distribution of mutations and mutation types across the ELF3 significant gene.
Figure S8. This figure depicts the distribution of mutations and mutation types across the PIK3CA significant gene.
Figure S9. This figure depicts the distribution of mutations and mutation types across the CDKN1A significant gene.
Figure S10. This figure depicts the distribution of mutations and mutation types across the STAG2 significant gene.
Figure S11. This figure depicts the distribution of mutations and mutation types across the ARID1A significant gene.
Figure S12. This figure depicts the distribution of mutations and mutation types across the ZFP36L1 significant gene.
Figure S13. This figure depicts the distribution of mutations and mutation types across the FGFR3 significant gene.
Figure S14. This figure depicts the distribution of mutations and mutation types across the RHOB significant gene.
Figure S15. This figure depicts the distribution of mutations and mutation types across the RHOA significant gene.
Figure S16. This figure depicts the distribution of mutations and mutation types across the HRAS significant gene.
Figure S17. This figure depicts the distribution of mutations and mutation types across the NFE2L2 significant gene.
Figure S18. This figure depicts the distribution of mutations and mutation types across the KRAS significant gene.
Figure S19. This figure depicts the distribution of mutations and mutation types across the KLF5 significant gene.
Figure S20. This figure depicts the distribution of mutations and mutation types across the EP300 significant gene.
Figure S21. This figure depicts the distribution of mutations and mutation types across the HIST1H3B significant gene.
Figure S22. This figure depicts the distribution of mutations and mutation types across the C3orf70 significant gene.
Figure S23. This figure depicts the distribution of mutations and mutation types across the FBXW7 significant gene.
Figure S24. This figure depicts the distribution of mutations and mutation types across the PSIP1 significant gene.
Figure S25. This figure depicts the distribution of mutations and mutation types across the FOXQ1 significant gene.
Figure S26. This figure depicts the distribution of mutations and mutation types across the RUNX1 significant gene.
Figure S27. This figure depicts the distribution of mutations and mutation types across the TSC1 significant gene.
Figure S28. This figure depicts the distribution of mutations and mutation types across the PTEN significant gene.
Figure S29. This figure depicts the distribution of mutations and mutation types across the METTL3 significant gene.
Figure S30. This figure depicts the distribution of mutations and mutation types across the ZNF511 significant gene.
Figure S31. This figure depicts the distribution of mutations and mutation types across the FOXA1 significant gene.
Figure S32. This figure depicts the distribution of mutations and mutation types across the DIAPH2 significant gene.
Figure S33. This figure depicts the distribution of mutations and mutation types across the ZFP36L2 significant gene.
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 24. Number of genes displayed: 10
| rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FGFR3 | fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) | 64 | 62 | 51 | 24490 | 34265 | 0 | 0 |
| 2 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 54 | 42 | 31 | 16590 | 150 | 0 | 0 |
| 3 | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 21 | 19 | 13 | 7505 | 2748 | 0 | 0 |
| 4 | TP53 | tumor protein p53 | 226 | 356 | 210 | 140620 | 46180 | 0 | 0 |
| 5 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 94 | 220 | 74 | 86900 | 35681 | 0 | 0 |
| 6 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 14 | 52 | 13 | 20540 | 147785 | 0 | 0 |
| 7 | FBXW7 | F-box and WD repeat domain containing 7 | 38 | 91 | 20 | 35945 | 549 | 0 | 0 |
| 8 | RB1 | retinoblastoma 1 (including osteosarcoma) | 73 | 267 | 43 | 105465 | 114 | 0 | 0 |
| 9 | CDKN2A | cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) | 30 | 332 | 30 | 131140 | 772 | 0 | 0 |
| 10 | ATM | ataxia telangiectasia mutated | 65 | 245 | 16 | 96775 | 23 | 0 | 0 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 5. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 23. Number of genesets displayed: 10
| rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARFPATHWAY | Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. | ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 | 16 | ABL1(9), CDKN2A(30), E2F1(3), MDM2(6), MYC(2), PIK3CA(94), PIK3R1(7), POLR1A(18), POLR1B(5), POLR1C(5), POLR1D(4), RAC1(4), RB1(73), TBX2(7), TP53(226) | 11787713 | 493 | 271 | 310 | 38 | 182 | 13 | 102 | 37 | 151 | 8 | <1.00e-15 | <1.00e-15 | <1.48e-13 |
| 2 | P53PATHWAY | p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. | APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 | 16 | APAF1(7), ATM(65), BAX(2), CCND1(4), CCNE1(3), CDK2(1), CDK4(6), CDKN1A(38), E2F1(3), GADD45A(1), MDM2(6), PCNA(4), RB1(73), TP53(226) | 10569238 | 439 | 266 | 312 | 31 | 118 | 9 | 95 | 30 | 173 | 14 | 1.07e-12 | <1.00e-15 | <1.48e-13 |
| 3 | SKP2E2FPATHWAY | E2F-1, a transcription factor that promotes the G1/S transition, is repressed by Rb and activated by cdk2/cyclin E. | CCNA1, CCNE1, CDC34, CDK2, CUL1, E2F1, RB1, SKP1A, SKP2, TFDP1 | 9 | CCNA1(4), CCNE1(3), CDC34(1), CDK2(1), CUL1(19), E2F1(3), RB1(73), SKP2(5), TFDP1(2) | 4966858 | 111 | 101 | 99 | 9 | 29 | 1 | 8 | 5 | 62 | 6 | 0.000161 | <1.00e-15 | <1.48e-13 |
| 4 | TIDPATHWAY | On ligand binding, interferon gamma receptors stimulate JAK2 kinase to phosphorylate STAT transcription factors, which promote expression of interferon responsive genes. | DNAJA3, HSPA1A, IFNG, IFNGR1, IFNGR2, IKBKB, JAK2, LIN7A, NFKB1, NFKBIA, RB1, RELA, TIP-1, TNF, TNFRSF1A, TNFRSF1B, TP53, USH1C, WT1 | 18 | DNAJA3(3), HSPA1A(3), IFNG(2), IFNGR1(1), IFNGR2(6), IKBKB(11), JAK2(8), LIN7A(3), NFKB1(3), NFKBIA(6), RB1(73), RELA(6), TNF(4), TNFRSF1A(5), TNFRSF1B(6), TP53(226), USH1C(10), WT1(4) | 10415274 | 380 | 237 | 263 | 31 | 112 | 7 | 91 | 22 | 140 | 8 | 6.85e-14 | 1.33e-15 | 1.48e-13 |
| 5 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | HDAC1(4), MYC(2), SP1(10), SP3(3), TP53(226), WT1(4) | 4101874 | 249 | 205 | 141 | 21 | 69 | 6 | 80 | 21 | 71 | 2 | 3.73e-09 | 1.33e-15 | 1.48e-13 |
| 6 | P53HYPOXIAPATHWAY | Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. | ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 | 19 | ABCB1(16), AKT1(3), ATM(65), BAX(2), CDKN1A(38), CPB2(5), CSNK1A1(6), CSNK1D(3), FHL2(4), GADD45A(1), HIF1A(6), HSPA1A(3), IGFBP3(1), MAPK8(5), MDM2(6), NFKBIB(6), TP53(226) | 12077203 | 396 | 261 | 276 | 37 | 124 | 11 | 102 | 32 | 119 | 8 | 2.30e-09 | 1.44e-15 | 1.48e-13 |
| 7 | PMLPATHWAY | Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. | CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 | 13 | CREBBP(50), DAXX(9), HRAS(21), PAX3(11), PML(14), RARA(6), RB1(73), SIRT1(9), SP100(13), TNF(4), TNFRSF1A(5), TNFRSF1B(6), TP53(226) | 10972480 | 447 | 258 | 318 | 32 | 119 | 5 | 124 | 30 | 160 | 9 | <1.00e-15 | 2.11e-15 | 1.86e-13 |
| 8 | PLK3PATHWAY | Active Plk3 phosphorylates CDC25c, blocking the G2/M transition, and phosphorylates p53 to induce apoptosis. | ATM, ATR, CDC25C, CHEK1, CHEK2, CNK, TP53, YWHAH | 7 | ATM(65), ATR(32), CDC25C(2), CHEK1(3), CHEK2(11), TP53(226), YWHAH(2) | 9369284 | 341 | 240 | 229 | 22 | 113 | 10 | 92 | 34 | 88 | 4 | 1.12e-10 | 3.00e-15 | 2.13e-13 |
| 9 | RBPATHWAY | The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. | ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH | 12 | ATM(65), CDC25A(5), CDC25B(2), CDC25C(2), CDK2(1), CDK4(6), CHEK1(3), MYT1(10), RB1(73), TP53(226), WEE1(10), YWHAH(2) | 10260649 | 405 | 252 | 287 | 31 | 112 | 10 | 93 | 32 | 149 | 9 | 8.30e-12 | 3.11e-15 | 2.13e-13 |
| 10 | G1PATHWAY | CDK4/6-cyclin D and CDK2-cyclin E phosphorylate Rb, which allows the transcription of genes needed for the G1/S cell cycle transition. | ABL1, ATM, ATR, CCNA1, CCND1, CCNE1, CDC2, CDC25A, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DHFR, E2F1, GSK3B, HDAC1, MADH3, MADH4, RB1, SKP2, TFDP1, TGFB1, TGFB2, TGFB3, TP53 | 25 | ABL1(9), ATM(65), ATR(32), CCNA1(4), CCND1(4), CCNE1(3), CDC25A(5), CDK2(1), CDK4(6), CDK6(5), CDKN1A(38), CDKN1B(6), CDKN2A(30), CDKN2B(3), E2F1(3), GSK3B(5), HDAC1(4), RB1(73), SKP2(5), TFDP1(2), TGFB1(3), TGFB3(1), TP53(226) | 17514723 | 533 | 279 | 396 | 42 | 158 | 15 | 113 | 39 | 193 | 15 | 2.11e-15 | 4.22e-15 | 2.45e-13 |
Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10
| rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PEPIPATHWAY | Proepithelin (PEPI) induces epithelial cells to secrete IL-8, which promotes elastase secretion by neutrophils. | ELA1, ELA2, ELA2A, ELA2B, ELA3B, GRN, IL8, SLPI | 3 | GRN(8) | 1005449 | 8 | 8 | 8 | 0 | 3 | 0 | 3 | 0 | 2 | 0 | 0.13 | 0.49 | 1 |
| 2 | HSA00902_MONOTERPENOID_BIOSYNTHESIS | Genes involved in monoterpenoid biosynthesis | CYP2C19, CYP2C9 | 2 | CYP2C19(7), CYP2C9(3) | 1188571 | 10 | 10 | 10 | 2 | 3 | 0 | 6 | 0 | 1 | 0 | 0.37 | 0.59 | 1 |
| 3 | HSA00785_LIPOIC_ACID_METABOLISM | Genes involved in lipoic acid metabolism | LIAS, LIPT1, LOC387787 | 2 | LIAS(5), LIPT1(1) | 897135 | 6 | 5 | 6 | 0 | 4 | 1 | 1 | 0 | 0 | 0 | 0.29 | 0.74 | 1 |
| 4 | HSA00730_THIAMINE_METABOLISM | Genes involved in thiamine metabolism | LHPP, MTMR1, MTMR2, MTMR6, NFS1, PHPT1, THTPA, TPK1 | 8 | LHPP(2), MTMR1(8), MTMR2(6), MTMR6(8), NFS1(5), THTPA(2), TPK1(4) | 3725882 | 35 | 32 | 35 | 4 | 20 | 0 | 5 | 5 | 5 | 0 | 0.07 | 0.75 | 1 |
| 5 | 1_AND_2_METHYLNAPHTHALENE_DEGRADATION | ADH1A, ADH1A, ADH1B, ADH1C, ADH1B, ADH1C, ADH4, ADH6, ADH7, ADHFE1 | 7 | ADH1A(5), ADH1B(3), ADH4(2), ADH6(7), ADH7(4), ADHFE1(4) | 3308380 | 25 | 24 | 25 | 3 | 11 | 1 | 6 | 2 | 5 | 0 | 0.065 | 0.78 | 1 | |
| 6 | HSA00627_1,4_DICHLOROBENZENE_DEGRADATION | Genes involved in 1,4-dichlorobenzene degradation | CMBL | 1 | CMBL(1) | 299386 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0.75 | 0.79 | 1 |
| 7 | SLRPPATHWAY | Small leucine-rich proteoglycans (SLRPs) interact with and reorganize collagen fibers in the extracellular matrix. | BGN, DCN, DSPG3, FMOD, KERA, LUM | 5 | BGN(2), DCN(3), FMOD(3), KERA(7), LUM(2) | 2112006 | 17 | 16 | 17 | 2 | 9 | 0 | 5 | 2 | 1 | 0 | 0.085 | 0.8 | 1 |
| 8 | IL18PATHWAY | Pro-inflammatory IL-18 is activated in macrophages by caspase-1 cleavage and, in conjunction with IL-12, stimulates Th1 cell differentiation. | CASP1, IFNG, IL12A, IL12B, IL18, IL2 | 6 | CASP1(9), IFNG(2), IL12A(1), IL12B(3), IL2(1) | 1737741 | 16 | 16 | 16 | 3 | 9 | 0 | 4 | 1 | 2 | 0 | 0.33 | 0.84 | 1 |
| 9 | HSA00950_ALKALOID_BIOSYNTHESIS_I | Genes involved in alkaloid biosynthesis I | DDC, GOT1, GOT2, TAT, TYR | 5 | DDC(8), GOT1(2), TAT(5), TYR(12) | 2741084 | 27 | 23 | 27 | 4 | 12 | 1 | 9 | 1 | 4 | 0 | 0.086 | 0.85 | 1 |
| 10 | TUBBYPATHWAY | Tubby is activated by phospholipase C activity and hydrolysis of PIP2, after which it enters the nucleus and regulates transcription. | CHRM1, GNAQ, GNB1, GNGT1, HTR2C, PLCB1, TUB | 7 | CHRM1(2), GNAQ(3), GNB1(7), HTR2C(1), PLCB1(17), TUB(4) | 4164702 | 34 | 31 | 33 | 4 | 19 | 2 | 9 | 3 | 1 | 0 | 0.022 | 0.88 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.